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Hospital Universitario Virgen de la Victoria, Facultad de Medicina, Campus Universitario de Teatinos s/n, Málaga, SpainSummary on statistical evaluations with large databases will provide widerDiagnosis of drug-induced liver injury (DILI) remains a
challenge and eagerly awaits the development of reliable hep-
atotoxicity biomarkers. Several methods have been developed
in order to facilitate hepatotoxicity causality assessments.
These methods can be divided into three categories: (1) expert
judgement, (2) probabilistic approaches, and (3) algorithms or
scales. The last category is further divided into general and
liver-speciﬁc scales.
The Council for International Organizations of Medical Sci-
ences (CIOMS) scale, also referred to as the Roussel Uclaf Causal-
ity Assessment Method (RUCAM), although cumbersome and
difﬁcult to apply by physicians not acquainted with DILI, is used
by many expert hepatologists, researchers, and regulatory
authorities to assess the probability of suspected causal agents.
However, several limitations of this scale have been brought to
light, indicating that a number of adjustments are needed. This
review is a detailed timely criticism to alert the readers of the
limitations and give insight into what would be needed to
improve the scale. Instructions on how to approach DILI diagnosis
in practice are provided, using CIOMS as an aid to emphasize the
topics to be addressed when assessing DILI cases.
Amendments of the CIOMS scale in the form of applying
authoritative evidence-based criteria, a simpliﬁed scoring system
and appropriate weighting given to individual parameters basedJournal of Hepatology 20
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Drug induced liver injury (DILI) is today a leading global health
problem. Idiosyncratic DILI, together with acetaminophen over-
dose, rank as the ﬁrst cause of acute liver failure in the US and
Sweden and are the main reasons for postmarketing regulatory
decisions, such as withdrawal of drugs from the market [1–3].
Almost any pharmaceutical or xenobiotic compound may induce
liver injury, rendering the diagnosis of DILI a challenging task for
health care professionals. In addition, robust DILI biomarkers spe-
ciﬁc and sensitive enough to distinguish DILI from other causes of
liver injury are absent. The development of such biomarkers
would not only facilitate DILI diagnosis, but would also enhance
DILI research and human risk assessments.
Efforts to enhance the identiﬁcation of adverse hepatic reac-
tions and to obtain reliable information about the epidemiology
and pathogenesis are being made worldwide. The Spanish DILI
Registry, set up in 1994, is a multicenter collaborative network
with a large database of prospectively recorded DILI cases [4].
The Drug Induced Liver Injury Network (DILIN) was established
in the US in 2003 to conduct research into the causes of DILI,
while DILIGEN is operating in England [5,6]. Collections of hepa-
totoxicity cases identiﬁed through pharmacovigilance systems
have also been set up, such as the Swedish adverse drug reactions
advisory committee (SADRAC) [7] and the EUDAGRENE project
[8]. These collaborative networks provide opportunities to agree
upon common deﬁnitions, diagnostic criteria, terminologies,
and improvements in causality assessment.
This review presents a summary of the most commonly used
causality assessment methods for adverse drug reactions (ADRs)
focusing on their strengths and drawbacks in determining causal-
ity in potential DILI cases and give insight into what would be
needed to improve the CIOMS scale. This review is also intended11 vol. 55 j 683–691
Liver injury
(clinical hepatitis or abnormal increase in liver tests)
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to give the reader detailed instructions on how to approach the
diagnosis of DILI in practice, using the CIOMS as a reminder of
the topics that need to be addressed when approaching DILI
cases.Suspicion of DILI
Retrieve history of drug and xenobiotic use
Exposure to potential DILI agent 
with compatible temporal sequence
NO
YES
Search for non-drug causes:
Alcohol abuse
Viral hepatitis (A, B, C, D, and E)
EBV and CMV
Bacterial or fungal sepsis
Autoimmune hepatitis
Inherited diseases (e.g. Wilson’s disease)
Congestive heart failure, ischemic liver
Primary or metastatic liver
Biliary tract or pancreatic carcinoma
Benign biliary obstruction
Search for culprit drug:
Hepatotoxic potential
Typical latency signature
Features strengthening DILI suspicion:
 drug allergy features
 rapid improvement upon dechallenge
 inadvertent rechallenge/previous drug 
 exposure
 suggestive liver biopsy features
 high CIOMS score 
Fig. 1. Approaching a suspected drug-induced hepatotoxicity case.Diagnosis of DILI
Prompt recognition of a culprit drug as the cause of liver injury is
themost important aspect in hepatotoxicity management, since it
appears to decrease the risk of progression to acute liver failure or
chronic liver injury [9]. Several aspects of DILI complicate its
diagnosis. Primarily, DILI may resemble any acute or chronic liver
disease and the ‘‘signature’’ (consistent clinical, pathological, and
latency presentations) for a given drug can vary. Secondly, there
is currently no ‘‘gold standard’’ for DILI veriﬁcation. The diagnosis,
therefore, depends heavily on exclusion of other causes of liver
injury with no end to possible exclusions that could be sought.
Key Points  
Until specific biomarkers for DILI become available the 
diagnosis relies on a systematic approach where 
chronology of drug administration and dechallenge with 
regard to the hepatic disease and careful exclusion of 
potential competing causes are crucial. 
It is unlikely that a single instrument would accommodate 
all forms of DILI presentation unless there is a dynamic 
weighting of the component variables. 
Among the available scoring methods for assessing DILI 
in clinical practice the CIOMS scale, although 
cumbersome and with flaws in intra- and interrater 
reliability, is currently the preferred method when 
approaching a suspicion of DILI. However, it does not 
substitute clinical judgment. 
Complex instructions, selection, and weighting of the 
criteria discrimination among concomitant drugs need to 
be addressed more adequately in the CIOMS scale. 
Likewise, liver biopsy findings and immunoallergic 
features should be incorporated in the scoring system. 
A future “tailored” computerised assessment scale that 
could incorporate information on known signatures, 
specific risk factors and authoritative evidence-based 
criteria for a given drug could be feasible through the 
analyses of current large databases of DILI patients. 
Diagnosis of idiosyncratic DILI requires high levels of suspi-
cion and is usually made after a retrospective review of the avail-
able data has been done. Evaluation of cases is not a
homogeneous process due to work-up variabilities resulting from
differences in clinical approaches and patient data availability.
Polypharmacy and the presence of concomitant diseases can fur-
ther impede DILI diagnosis. Gathering the necessary information
at the time the illness is just unfolding improves the chances of
accurate diagnosis and consequently patient outcome. A careful
step-by-step approach to diagnosis is recommended (Fig. 1).684 Journal of Hepatology 201Initiatives to homologize DILI assessments have been taken,
with a recently held international clinical research workshop
focused on standardizing current nomenclature and terminology
implicated in DILI research [10]. Likewise, the International
Severe Adverse Events Consortium (iSAEC) Phenotyping Stan-
dardization Project (PSP) is currently working towards achieving
consistency, homogeneity, and objectivity in the deﬁnition, char-
acterization, and classiﬁcation of clinical DILI syndromes [11].Causality assessment methods
DILI causality assessment has been a subject of interest and
debate for years. Several standardized systems have been pro-
posed to assess the relationship between drugs and the appear-
ance of adverse events. Those systems belong to three
categories: expert judgement, probabilistic methods, and algo-
rithms or scales.1 vol. 55 j 683–691
Table 1. Strengths and weaknesses of standardized causality assessment scales and algorithms in evaluation of suspected DILI cases.
Strengths 
srotaulaveneewtebytilibicudorperrettebedivorP
stnemssessaesacniytivitcejboecnahnE
seirogetacdaorbniytilibaborpfohtgnertsehtedarG
srekrowILIDroflootgnihcaettnellecxE
 Act as a checklist for information needed from the case
 Valuable in assessment of complex cases or in research settings 
rofsngisgninrawlacituecamrahpfonoitcetedylraeedivorpnaC
regulatory measurements
Weaknesses 
 Often complex and time consuming 
 Do not provide certainty of case diagnosis 
 Do not substitute clinical judgement 
 Lack of case information or follow-up data leads to reduced 
probability   
 Do not discriminate among concomitant drugs 
 Evaluation of fatal or atypical cases remains challenging
Restrictive criteria and arbitrary weighting of factors may lead 
to incorrect evaluations
JOURNAL OF HEPATOLOGYExpert judgement
Expert judgement relies on professional opinions on causality
after considering all available and relevant data on the case
[12]. This approach is similar to clinical diagnosis. Hence, it suf-
fers the same limitation: subjectivity [13]. However, some
authors, such as Macedo et al., defend the expert judgement
method, due to greater speciﬁcity showed by this approach when
compared with several general algorithms [14]. Today, the most
detailed and standardized expert opinion method is used by the
DILIN study group [15]. This group attempts to minimize individ-
ual biases and inter-rater variability by producing a consensus
from three expert opinions. An obvious problemwith this system,
however, is the absence of an expert panel in daily clinical
practice.
Probabilistic methods
Most probabilistic approaches are derived from the Bayes’ theo-
rem, a mathematical representation of the relationship between
one conditional probability and its inverse [13]. This procedure
respects the basic rule of the probability theory, which states that
in the absence of any relevant information one should obtain a
neutral estimate. This is clearly advantageous in DILI causality
assessments where an incomplete work-up is a common occur-
rence in clinical practice. However, the requirement of precise
data from a large number of cases to model probability distribu-
tion for each parameter limits the applicability of this approach,
as DILI is a relatively rare condition. Nevertheless, probabilistic
methods have been tested in hepatotoxicity [16].
Scales and algorithms
Scales and algorithms are useful ways of weighting the evidence
concerning adverse drug reactions (ADRs). They provide not only
a diagnostic tool but also a checklist to help gather the informa-
tion required, by reminding clinicians of the topics to be
addressed when a case is assessed. Algorithmic approaches are
widely used for operational assessments of ADRs, not only due
to their appealing simplicity (successive evaluation of criteria,
sum of scores or decision trees), but also for requiring less subjec-
tive judgements. However, assessments with a given algorithm
strongly depend on the weight given to the criteria. The validity
of assessment scales will, therefore, drop if the correct weightsJournal of Hepatology 201have not been allocated to the parameters. A major problem cur-
rently hindering the validation of ADR causality algorithms in
DILI assessments is the absence of a diagnostic ‘gold standard’
to deﬁne the truth. Advantages and disadvantages of standard-
ized causality assessment scales and algorithms in DILI evalua-
tion are outlined in Table 1. The scale and algorithm methods
can be further divided into general systems for causality assess-
ment of non-speciﬁc ADRs and liver-speciﬁc scales for DILI.
General scales and algorithms
The ﬁrst ones to develop operational diagnostic criteria for iden-
tiﬁcation of ADRs were Karch and Lasagna in 1977 [17]. Their
approach has two major limitations. Firstly, it is impossible to
identify the ﬁrst case of ADR as deﬁnitive for a drug not previously
implicated in ADRs. Secondly, subjective judgement is needed for
many of the steps, making the method more prone to bias.
An alternative algorithm, the Naranjo Adverse Drug Reaction
Probability Scale (1981) offers the advantage of simplicity and
wide applicability [18]. This scale involves ten ‘‘yes’’, ‘‘no’’, or
‘‘unknown/inapplicable’’ questions that provide a probability cat-
egory based on the total score. The scale was validated and dem-
onstrated improved assessment reproducibility. However, the
Naranjo scale showed low sensitivity and negative predictive
value in a recent comparison with the Council for International
Organizations of Medical Sciences (CIOMS) method in 225 sus-
pected hepatotoxicity cases [19]. This study concluded that the
Naranjo scale lacks in validity and reproducibility when evaluat-
ing DILI. Indeed, the Naranjo method was not designed for assess-
ing hepatotoxicity but for assessing ADRs in general. It therefore,
contains questions not relevant to idiosyncratic reactions and is
subsequently not recommended for hepatotoxicity assessments.
Speciﬁc causality assessment scales for DILI
Given the low validity and reproducibility of general methods
when assessing hepatotoxic events, several groups have
attempted to develop objective, systematic methodologies for
evaluating this type of ADR [20–23]. The ﬁrst causality assess-
ment method for drug-induced liver injury was the decision tree
developed by Stricker in 1992 [20]. This model assesses the
degree of certainty on a scale of several levels. Unfortunately,
Stricker’s decision tree is a complex and perhaps overly subjec-
tive method for use in routine clinical practice.1 vol. 55 j 683–691 685
Table 2. The most representative liver-speciﬁc causality assessment scales.
CIOMS MARIA & VICTORINO DDW-J 
Axis  Score Axis Score Axis Score 
Chronological criteria : 
tesnolitnuekatnigurdmorF
tesnolitnulawardhtiwgurdmorF
Course of the reaction   
Risk Factors  
Concomitant therapy  
Exclusion of other causes  
Previous information  
Rechallenge  
+1 to +2 
  0 to +1 
-2 to +3 
  0 to +2 
-3 to 0 
-3 to +2 
  0 to +2 
-2 to +3 
Chronological criteria  
From drug intake until onset  
From drug withdrawal until onset  
Course of the reaction  
Exclusion of other causes  
Extrahepatic manifestations 
Rechallenge 
Known reaction  
+1 to +3  
-3 to +3 
0 to +3 
-3 to +3 
0 to +3
+3  
-3 to +2  
Chronological criteria  
From drug intake until onset  
From drug withdrawal until onset 
Course of the reaction  
Risk Factors 
Exclusion of other causes 
Previous information 
Rechallenge  
Extrahepatic manifestations  
DLST 
+1 to +2
0 to +1
3+ot2-
1+ot0
-3 to +2 
0 to +1
3+ot0
1+ot0
2+ot0
Scores:  Scores:  
1-2 points unlikely 6-9 points unlikely 
<0 points excluded   <6 points excluded  
Scores:  
>8 points definite  >17 points definite  >4 points definite  
6- 8 points probable  14-17 points probable 3-4 points probable
3-5 points possible 10-13 points possible <3 points unlikely  
CIOMS, Council for the International Organization of Medical Sciences; DDW-J, Digestive Disease Week-Japan; DLST, Drug lymphocyte stimulation test.
ReviewInitiated in 1989, the CIOMS coordinated several meetings
with a panel of experts to develop an objective and consistent
DILI causality assessment algorithm. This led to the publication
of the Roussel Uclaf Causality Assessment Method (RUCAM) in
1993 [21]. This method, which we will be referring to as the
CIOMS scale, is based on the international DILI consensus criteria
that were published a few years earlier [24]. The scale applies
numerical weighting to key features in seven different domains:
chronology (latency and dechallenge), risk factors, concomitant
drug use, search for other aetiologies, existing information on
the drug’s hepatotoxic potential, and response to rechallenge.
The numerical weight given to each key feature is summed up
to generate an overall score that reﬂects the causality probability
(highly probable, probable, possible, unlikely, or excluded). The
system handles hepatocellular and cholestatic/mixed reactions
differently, recognizing that the latter may occur after a longer
post-cessation period and resolves more slowly.
This method, when ﬁrst validated, demonstrated 86% sensitiv-
ity, 89% speciﬁcity and positive and negative predictive values of
93% and 78%, respectively, using a cut-off point of 5 [25]. How-
ever, the validation of this system can be questioned as there
was, and still is, no true diagnostic ‘‘gold standard’’ available to
correctly verify DILI. Nevertheless, the DILI cases included in this
validation were cases with a positive drug rechallenge, which is
currently the major evidence recognized for conﬁrming DILI.
The reproducibility of the scale was evaluated by applying the
CIOMS to 50 suspected DILI cases by four experts. Agreement
between two, three, and four experts was 99%, 74%, and 37%,
respectively, indicating perturbing discrepancies as the number
of raters increases [21]. The CIOMS scale also demonstrated lim-
ited reliability in a recent DILIN study, where 40 DILI cases were
assessed by three independent raters and reassessed by the same686 Journal of Hepatology 201raters ﬁve months later. Complete agreement was only seen in
26% of the cases and the intra- and inter-rater reliability were
0.54 and 0.45, respectively [26].
In 1997, Maria and Victorino developed a simpliﬁed scoring
system in an attempt to overcome the complexity of the CIOMS
system. This system, referred to as the Clinical Diagnostic Scale
(CDS) or the M&V scale, uses several features of the CIOMS scale,
but focuses on less components [22]. The overall score corre-
sponds to ﬁve probability degrees: deﬁnite, probable, possible,
unlikely, and excluded. The M&V scale was validated using real
and ﬁctitious cases and compared with the classiﬁcation of three
external experts. The comparison showed 84% agreement
between the scale and expert opinions [22]. However, the authors
themselves implementing the scale assessments might have
enhanced the scale’s performance.
Nonetheless, the M&V scale has limitations. The scale classi-
ﬁes cases as deﬁnite only when ‘‘positive rechallenge’’ and hyper-
sensitivity features are present, despite these features being
comparatively infrequent in DILI [4]. Besides, the instrument per-
forms poorly in atypical cases, such as those with unusually long
latency periods or those leading to chronic evolution after drug
withdrawal [27]. In addition, drugs with more than ﬁve years
on the market and no documented hepatotoxicity potential are
given a lower score and criteria for exclusion of alternative causes
are poorly described. Taken together, these limitations make it
difﬁcult to generate high scores for most hepatic reactions and
to ascertain a diagnosis of drug-related hepatotoxicity with
conﬁdence.
A new diagnostic scale, the Digestive Disease Week-Japan
(DDW-J) scale, was recently proposed in Japan. This scale was
derived from the CIOMS scale, but with modiﬁcations in the
items concerning chronologic criteria, concomitant drug(s), and1 vol. 55 j 683–691
Table 3. Summary of validity and comparative studies between different causality assessment methods.
Studies Compared methods Number 
of cases
 Agreement 
and validity
 Comments 
Lucena et al SMOIC]72[.  vs. M&V Kdna%81512 w 0.28 
M&V: S 37%, Sp 100%, 
>agreement in HS cases 
<agreement in cholestasis, ALF, 
longer latency period, death and 
liver transplant cases
Aithal et al ]13[. M&V vs. International 
Consensus Criteria
%29pS,%88S:V&M531 The authors concluded that the M&V 
scale correlated well with consensus 
A large proportion of the cases 
.serutaefSHdetneserp
Watanabe et al. [28] DDW-J vs. CIOMS vs. J-WDD721V&M vs. CIOMS: Kw 0.03 
CIOMS vs. M&V: Kw 0.35
DDW-J and CIOMS are better than M&V 
DDW-J:  >S but <Sp 
García-Cortés et al. [19] CIOMS vs. Kdna%42522ojnaraN w 0.15 
Naranjo: S 54%, Sp 88%, 
Naranjo : interrater 45%, Kw 0.17
CIOMS: interrater 72%, Kw 0.71  
The Naranjo scale lacks validity
.sesacILIDniytilibicudorperdna
Rockey et al OES]51[. vs. CIOMS 24.0:rs’namraepS781
SEO: interrater 27% 
CIOMS: interrater 19% 
The SEO produced higher  
interrater agreement and likelihood 
scores than the CIOMS.
PPV 100%, NPV 25%
PPV 95%, NPV 29%
classification. 
ALF, acute liver failure; CIOMS, council for the international organization of medical sciences; DDW-J, digestive disease week-Japan; HS, hypersensitivity; Kw, weighted
kappa; M&V, Maria, and Victorino scale; NPV, negative predictive value; PPV, positive predictive value; S, sensitivity; SEO, structured expert opinion method; Sp, speciﬁcity.
JOURNAL OF HEPATOLOGYextra-hepatic manifestations [23]. The DDW-J scale has been
shown to accurately diagnose DILI and to be superior to the
CIOMS and M&V scale [28]. The DDW-J scale includes an
in vitro drug lymphocyte stimulation test (DLST) evaluation crite-
rion. Limited access and lack of standardization have prevented
generalized clinical use of the DLST outside Japan and conse-
quently DDW-J scale applications. However, recent ﬁndings of
speciﬁc HLA allele associations with DILI, suggesting an impor-
tant role for the adaptive immune response in DILI pathogenesis
[29], have highlighted the DLST’s potential value, and promoted a
new interest for lymphocyte-based tests in DILI assessments [30].
A comparison of domains and corresponding score allocations in
the three most representative liver-speciﬁc causality assessment
scales is featured in Table 2.
Various studies have examined the level of agreement
between causality assessment methods, in particular the CIOMS
and the M&V systems. A comparison of these two methods in
215 suspected DILI cases demonstrated low consistency between
the two systems [27]. Absolute agreement between the scales
was only observed in 42 cases (18%). The CIOMS scale showed
better discriminative power and produced assessments closer
to those of specialists.
The M&V scale was also compared with the international con-
sensus criteria in 135 reported hepatic ADRs [31]. Reports classi-
ﬁed as drug-related with the consensus criteria scored higher
with the M&V scale than those classiﬁed as drug-nonrelated or
indeterminate. Aithal and co-workers suggested that a cut-off
score >9 could identify all drug-related liver injuries, unless alter-
native diagnoses are strongly suspected. This seems a precarious
conclusion considering the proposed cut-off score falls into theJournal of Hepatology 201‘‘possible’’ category in the M&V scale, which makes it unreliable
for decision making.
A comparison between the DILIN group’s structured expert
opinion method and a ﬁve-category CIOMS scale in 187 sus-
pected DILI cases (each assessed by three independent reviewers)
showed initial complete agreement in 27% and 19% of cases,
respectively, with modest correlation between the two methods
(Spearman’s r = 0.42). The evaluation also demonstrated a shift
of the causality likelihood towards lower probabilities with the
CIOMS method [15]. The ﬂaw in intra- and inter-rater reliability
demonstrated for the CIOMS scale is a concern and casts doubts
on the validity of this method in its current state. Besides, one
unique instrument could hardly accommodate all the complexi-
ties posed by DILI. A summary of the different comparative stud-
ies focused on in this review is shown in Table 3.
The way in which hepatotoxicity diagnosis is reached was
evaluated in 61 DILI cases reported to the PubMed database dur-
ing the last decade. While the CIOMS was found to be the most
frequently used scale (16.4%) followed by the Naranjo (13.1%),
more than 62% of the reports did not use any causality assess-
ment method [32]. This highlights the fact that diagnostic scales
do not substitute for clinical judgement. Indeed, such methods
only translate the clinician’s suspicion into a quantitative score
and are designed for supporting rather than excluding causality.Strengths and limitations of the CIOMS scale
Due to heterogeneous DILI symptoms and variability among
drugs and individuals, it is unlikely that a unique assessment1 vol. 55 j 683–691 687
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instrument would ﬁt all forms of presentations. The CIOMS scale
offers a reasonable balance between the demands for absolute
scientiﬁc objectivity and the necessity of having a simple enough
method for practical use, and is consequently used by many
experts in the ﬁeld. Nevertheless, the CIOMS scale on its own is
ﬂawed for DILI diagnosis, an observation also made in recent
additional reviews on the topic [33,34].
The CIOMS scale has, however, room for improvements. Difﬁ-
culties in how to apply the scale are a serious setback and none of
the risk factors focused on in the CIOMS scale has been proven to
play a conclusive role in determining hepatotoxicity causality. In
addition, the signiﬁcance of the numerical weight given to each
domain is questionable. Incomplete patient work-ups, atypical
presentations of DILI, and concomitant drugs are other parame-
ters that are managed inadequately in the scale. The emerging
new data on DILI and the practical experience with the CIOMS
method over the last decade have resulted in a need for a CIOMS
scale ‘facelift’.
Complex instructions
The initial step when applying the CIOMS system is to deﬁne the
type of liver injury based on the pattern of serum enzymes by cal-
culating the ‘‘R ratio’’ [24].
R ¼ ðALT value=ALT ULNÞ=ðALP value=ALP ULNÞ
An R value greater or equal to 5 deﬁnes hepatocellular dam-
age, smaller or equal to 2 deﬁnes cholestatic damage, and cases
with an R value between 2 and 5 are considered as having mixed
type of liver injury. Depending on the pattern of liver damage,
some items in the scale will score differently. Importantly, mixed
type of damage fall into the cholestatic damage category
although no data support strict resemblance in disease manifes-
tation, severity, and progression. Furthermore, the type of liver
injury may change along the course of the illness [9]. Due to vari-
ations in the serum enzyme proﬁle during disease progression,
the time point for calculating the R value is important. Many cli-
nicians use enzyme values from the ﬁrst analytical test showing
elevations above normal to establish the R value, while others use
peak values, which may or may not coincide with the initial ana-
lytical values. The lack of clear instructions for how the R value
should be calculated can lead to differences among users in deﬁn-
ing the type of liver injury.
Selection and weighting of criteria
Another important limitation is represented by the domains and
the corresponding weightings. The CIOMS domains were selected
based on expert opinions and, therefore, lack scientiﬁc evidence
supporting a role in hepatotoxicity. Likewise, the weighting of
the criteria has not been derived from appropriate statistical
approaches, but was determined relatively arbitrarily by a group
of experts. This can potentially lead to incorrect assessment
results.
Time to onset
The latent period for DILI can vary considerably. The CIOMS scale
contains two items in this domain: time to onset from the begin-
ning and cessation of the drug. Since it is not stated that the items
are mutually exclusive some clinicians add the score from both of688 Journal of Hepatology 201these items to the total sum, generating a greater numerical
value. In addition, the CIOMS does not assign points for reactions
that start more than 15 or 30 days after ceasing drug administra-
tion in hepatocellular and cholestatic/mixed cases, respectively.
This aspect should be modiﬁed to take into account known data
on delayed appearance of hepatotoxicity for certain drugs, such
as amoxicillin–clavulanate [35].
Course of the reaction
Often the time taken to restore normal liver test values is not
clear, especially when blood tests are not available at day 8 or
30 for hepatocellular injury or at day 180 for cholestatic/mixed
type of liver damage, as requested by the CIOMS scale. Besides,
for many drugs the liver injury may worsen for days or weeks
after stopping the responsible drug, leading to a lower score.
Adaptation and normalization of liver tests can also occur despite
the continuation of the offending drug (so-called ‘‘tolerance’’) and
is not compatible with the current CIOMS criteria. In cases with
aberrant reaction course, such as long term cholestasis or cases
of acute liver failure leading rapidly to death or liver transplanta-
tion, the CIOMS scale tends to give lower probability scores and
consequently under-diagnoses cases in this category [27].
Risk factors
In the CIOMS scale, old age is considered a risk factor and a
patient age over 55 years scores an extra point. However, recent
data from a large cohort indicate that older age does not predis-
pose to overall DILI, but can be a predictor of cholestatic damage
while younger age seems to be related to heptocellular pattern of
injury [36]. Separate studies have also shown that age may be a
risk factor for particular forms of DILI, such as ﬂucloxacillin and
isoniazide-induced liver injury [37,38]. Alcohol is another risk
factor in the CIOMS scale. Alcohol use per se is not known to
increase the risk of idiosyncratic DILI development. Moreover,
evidence that chronic alcohol intake increases DILI susceptibility
is based on ﬁndings with limited number of drugs, and may not
be universally applicable [39]. Hence, the point given for alcohol
intake in the CIOMS scale, without differentiating time, amount,
and duration of consumption, is by no means justiﬁed.
The diversity and complexity of DILI is reﬂected in the emerg-
ing data of speciﬁc risk factors, such as enhanced risk of valproate
hepatotoxicity with concomitant use of other anticonvulsants or
increased antiretroviral hepatotoxicity in patients co-infected
with HBV or HCV and HIV [39]. Such risk factors are disregarded
in the CIOMS scale. Most experts agree today that genetic varia-
tions are probably the greatest risk factor for DILI [40]. Recent
studies have shown, for example, that presence of HLA alleles
B⁄5701, DRB1⁄0701, and DRB1⁄1501 are associated with ﬂucloxa-
cillin, ximelagatran, and amoxicillin–clavulanate hepatotoxicity,
respectively [6,40]. As new data unfold, extending the risk factor
domain in the CIOMS scale will be crucial to validate DILI.
Concomitant drugs
A major limitation of the CIOMS scale is the inability to ascertain
causality when two or more drugs are taken concomitantly, espe-
cially if having the same temporal sequence. In DILI cases with
concomitant drugs the CIOMS scale requires individual assess-
ments for each of the drugs. Concomitant use of another drug1 vol. 55 j 683–691
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with compatible or suggestive time to onset subtracts one point,
but two points if the concomitant drug is known to be hepato-
toxic. Should we subtract one point to the score achieved by a
known hepatotoxic drug, such as amoxicillin–clavulanate, for
the concomitant use of a bronchodilator? On the contrary, the
term hepatotoxic is often subject to variable interpretations,
which may lead to bias towards certain drugs. Likewise, the
CIOMS scale disregards differences in metabolic pathways used
by concomitant drugs and consequent potential pharmacokinetic
drug–drug or drug–disease interactions [41].
Search for non-drug causes
The CIOMS scale includes a list of common disorders that should
be excluded in order to more conﬁdently ascribe hepatic injury to
the drug. However, this list is not exclusive. In practical terms,
one would expect the clinician to rule out at least acute hepatitis
A, B, and C, in addition to biliary problems, autoimmune, and
alcoholic hepatitis and circumstances that produce ischaemic–
hypoxic liver injury.
There are liver diseases less frequently considered that should
preferably be included in the list, such as hepatitis E; acute exac-
erbation of chronic hepatitis B, C, or D; worsening of non-alco-
holic fatty liver disease; metabolic disorders e.g. Wilson’s
disease; vascular pathology and oncologic liver disease [42]. In
the case of hepatitis E, Dalton and co-workers have shown that
21% of patients with criterion-referenced DILI had autochthonous
hepatitis E. Based on their ﬁndings, they suggest that a diagnosis
of DILI is not secure without testing for HEV [43].
Previous information on hepatotoxicity of the drug
Scoring previous knowledge of drug hepatotoxicity potentials
will only be reproducible if there is a common data source with
continuous updating of the information, or the judgement will
be largely dependent on each evaluator’s state of information
[21]. This CIOMS score can be particularly difﬁcult to assign as
summary of product characteristics of drugs may not be easily
accessible and are not always informative enough. Many drugs
have notes in their summary of product characteristics indicating
some form of liver enzyme alterations. However, the degree of
hepatic effects is often not detailed. The meaning of ‘hepatotoxic-
ity potential’ is, therefore, left to the evaluator to interpret, inev-
itably leading to variations between assessors.
Herbal and dietary supplements are even less likely to be
complemented with hepatotoxicity information and the task
can be more difﬁcult due to lack of information on the active
ingredient(s). For drugs with no previous information on hepato-
toxicity, no points are given in the CIOMS scale. This, however,
does not accurately reﬂect the drug’s hepatotoxicity potential.
The development of an international database with an up-to-date
list of hepatotoxins would facilitate DILI diagnosis and enhance
the accuracy. An initial attempt was made recently, whereby a
list of drugs associated with hepatotoxicity in three major DILI
registries in Spain, the US, and Sweden was assembled [44].
Response to rechallenge
Drug rechallenge is arguably the most deﬁnitive means of DILI
diagnosis, but is rarely performed due to the risks involved. A
recent analysis of the performance of the CIOMS scale in theJournal of Hepatology 201Spanish DILI Registry showed that rechallenge data were absent
in >95% of all cases. While immunoallergic DILI reactions often
produce a rapid response, drugs triggering metabolic idiosyn-
crasy can have highly variable and delayed responses to re-
administration. Interpretation of such reactions can, therefore,
be difﬁcult and potentially lead to erroneous assumptions [45].
Due to the infrequency of rechallenge, a simpliﬁcation of the four
response categories in the CIOMS scale’s rechallenge domain
seems feasible and should be addressed.
Histological ﬁndings
The role of liver biopsy in DILI diagnosis is a controversial issue.
This technique is not routinely performed for diagnostic indica-
tion. Liver biopsy should be performed though when the patient
may have an underlying liver injury or to characterize injury pat-
terns from drugs not previously imputed in DILI and to identify
more severe or residual lesions that could have prognostic signif-
icance [46]. Histological information may also allow more conﬁ-
dent exclusion of common liver conditions and subsequently
strengthen a DILI diagnosis.
The presence of biopsy ﬁndings suggestive of DILI, such as
demarcated perivenular (acinar zone 3) necrosis, minimal hepati-
tis with canalicular cholestasis, poorly developed portal inﬂam-
matory reaction, abundant neutrophils, abundant eosinophils,
epithelioid-cell granulomas, microvesicular steatosis, and the
presence of drug deposits (vitamin A autoﬂuorescence) should
upgrade the causality assessment score [47,48].Future prospects
A focussed effort on developing stricter deﬁnitions and conve-
niently standardized means of evaluating hepatotoxicity through
large scale collaborative approaches would greatly improve DILI
causality assessments. It is unlikely that a single instrument will
be accurate and reliable for all patients with suspected toxic liver
disease from any agent unless there is a dynamic weighting of the
component variables. Although difﬁcult to apply and non-user-
friendly the CIOMS method is the most frequently used DILI cau-
sality scale and is applied by many DILI experts, researchers, and
regulatory authorities to assess the probability of suspected cau-
sal agents.
To overcome difﬁculties in DILI causality assessment and to
more reliably ascertain causal agents, the CIOMS scale needs to
be reﬁned. Amendments in the form of applying authoritative
evidence-based criteria, a simpliﬁed scoring system, and appro-
priate weighting given to individual parameters based on statis-
tical evaluations with large databases, are devised to provide
wider applicability in the clinical setting.
This will now be feasible thanks to the many large DILI regis-
tries with large data sets established around the world. This
invaluable source has brought to light the variability in DILI man-
ifestation and consequent need for ‘tailored’ CIOMS scales. The
ability to incorporate information on the known signature of a
given drug and speciﬁc risk factors could strengthen the assess-
ment. In particularly, accommodating the emerging data on
genetic predisposition to DILI is highly desirable. However, to
manage and incorporate the ever growing data on DILI a comput-
erized assessment scale would be the preferred option. DILIN has
expressed interest in developing a web-based causality assess-1 vol. 55 j 683–691 689
Review
ment system in conjunction with a comprehensive DILI database
in collaboration with the National Library of Medicine [5].
The CIOMS scale efﬁciency is dependent on the amount of
available data for the case. Subsequently, early suspicion of DILI
often leads to a low CIOMS scale probability score due to lack
of data, such as response to dechallenge. The development of
an abridged scale, requiring limited data, for early assessments
would be an important goal in terms of faster DILI recognition
and subsequent treatment for the patient [49]. Work in this area
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On behalf of the Spanish group for the Study of Drug-Induced
Liver Disease Participating clinical centres:
Hospital Universitario Virgen de la Victoria, Málaga (centro
coordinador): R.J. Andrade, M.I. Lucena, M. García-Cortés, A
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Hospital Torrecárdenas, Almería: M.C. Fernández, G. Peláez, R.
Daza, M. Casado, J.L. Vega, F. Suárez, M. Torres, M. González-
Sánchez, J. Esteban.
Hospital Universitario Virgen de Valme, Sevilla: M. Romero-
Gómez, L. Grande, M. Jover, B. Prado.
Hospital de Mendaro, Guipúzkoa: A. Castiella, E.M. Zapata.
Hospital Germans Trias i Puyol, Barcelona: R. Planas, J. Costa,
A. Barriocanal, E. Montané, S. Anzola, N. López, F. García-Gón-
gora, A. Borras, E. Gallardo, A. Vaqué, A. Soler.
Hospital Virgen de la Macarena, Sevilla: J.A. Durán, I. Carmona,
A. Melcón de Dios, M. Jiménez, J. Alanís- López, M. Villar.
Hospital Central de Asturias, Oviedo: R. Pérez-Álvarez, L. Rodr-
igo-Sáez.
Hospital Universitario San Cecilio, Granada: J. Salmerón, A.
Gila.
Hospital Costa del Sol, Marbella (Málaga): J.M. Navarro, J.F.
Rodríguez, I.M. Mendez Sánchez.
Hospital Universitario Virgen de lãs Nieves, Granada: R. Mar-
tín-Vivaldi, F. Nogueras.
Hospital Sant Pau, Barcelona: C. Guarner, G. Soriano, E.M.
Román.
Hospital Puerta del Mar, Cádiz: F. Díaz, M.J. Soria, P. Rendón,
M. Macías.
Hospital Morales Meseguer, Murcia: H. Hallal, E. García Oltra.
Hospital 12 de Octubre, Madrid: T. Muñoz-Yagüe, J.A. Solís-
Herruzo.
Hospital Marqués de Valdecilla, Santander: F. Pons, M. Arias.690 Journal of Hepatology 201Hospital Xeral-Calde, Lugo: S. Ávila-Nasi.
Hospital de Donosti, San Sebastián: M. García-Bengoechea, J.
Arenas, M.I. Gomez Osua.
Hospital de Basurto, Bilbao: S. Blanco, P. Martínez-Odriozola.
Hospital Carlos Haya, Málaga: M. Jiménez, R. González-
Grande.
Hospital de Puerto Real, Cádiz: J.M. Pérez-Moreno, M. Puertas.
Hospital del Mar, Barcelona: R. Solá.
Hospital General Básico de Vélez, Málaga: F. Santalla, C. Sán-
chez-Robles.
Hospital General Universitario Gregorio Marañón, Madrid: R.
Bañares.
Hospital de Sagunto, Valencia: J. Primo, J.R. Molés.
Hospital de Laredo, Cantabria: M. Carrascosa.
Hospital Clínic, Barcelona: M. Bruguera, P. Gines, S. Lens.
Hospital Universitario de Canarias, La Laguna, Tenerife: M.
Hernandez-Guerra.
Hospital Infanta Cristina, Badajoz: J.L. Montero.
Hospital Puerta de Hierro, Madrid: J.L. Calleja, J. de la Revilla.
Hospital Del Tajo, Aranjuez, Madrid: O. Lo lacono.
Hospital La Fe, Valencia: M. Berenguer.
Hospital Doctor Peset, Valencia: A. del Val.
Hospital La Línea, Algeciras, Cádiz: E. García Ruiz.
Hospital Universitario Virgen de la Arrixaca, Murcia: M. Miras
Lopez.
Hospital de Albacete, Albacete: J.M. Moreno.
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